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DISPATCHES

Mycobacterium
ulcerans Infection
Imported from
Australia to
Missouri,
USA, 2012
Benjamin Stuart Thomas, Thomas C. Bailey,
Julu Bhatnagar, Jana M. Ritter, Brian D. Emery,
Omar W. Jassim, Ian Kerst Hornstra,
and Sarah L. George
Buruli ulcer, the third most common mycobacterial disease worldwide, rarely affects travelers and is uncommon
in the United States. We report a travel-associated case
imported from Australia and review 3 previous cases diagnosed and treated in the United States. The differential
diagnoses for unusual chronic cutaneous ulcers and those
nonresponsive to conventional therapy should include Mycobacterium ulcerans infection.

B

uruli ulcer disease, caused by Mycobacterium ulcerans, is the third most common mycobacterial disease
worldwide. Cases are concentrated in sub-Saharan Africa
but also occur in subtropical and nontropical regions (e.g.,
Australia and Japan) (1). M. ulcerans disease is not endemic to the United States, but rare cases have been reported
in travelers returning from regions where the organism is
endemic (2–4). We describe M. ulcerans infection in a man
who returned to the United States after living abroad and
review M. ulcerans cases reported in 3 travelers.
The Case
In December 2012, after unsuccessful treatment elsewhere, a 63-year-old white man was referred to the Veterans Affairs Medical Center, St. Louis, Missouri, USA,
for evaluation of skin ulcers. Previous medical history indicated hypertension and hyperlipidemia. The patient sought
care in April 2012 for a persistent, nonpainful ulcer (1-cm
diameter) on his right medial calf (Figure). No previous
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episodes or other symptoms of infection were reported.
The patient had lived abroad for >10 years and had recently
returned to the United States from Queensland, Australia,
where he spent his last month hiking in the Daintree Rainforest. His health care providers recommended topical antimicrobial drugs and wound care, and a punch biopsy was
obtained but the specimen was not stained or cultured for
acid-fast bacilli (AFB). Pathologic findings on the biopsy
specimen were nonspecific (reactive epidermal changes
and ulceration).
Between April and July 2012, the ulcer increased to
4 cm despite multiple debridements. In September a painful, warm, erythematous lesion developed on the patient’s
left great toe. He consulted physicians in numerous subspecialties and underwent 2 more biopsies; specimens were
not initially stained or cultured for AFB. Pathologic findings from the specimens showed extensive necrosis without granulomas. The ulcers were diagnosed as pyoderma
gangrenosum with bacterial superinfection, and treatment
was initiated with oral antimicrobial drugs (amoxicillin/
clavulanate 875/125 mg twice daily) and prednisone (60
mg/day). Transient improvement occurred, but in late November, the toe lesion worsened.
When the patient was referred to the Veteran’s Affairs
Medical Center in December 2012, biopsies were again
obtained; pathologic evaluation showed extensive necrosis
(without granulomas) and numerous AFB. Fresh frozen tissue was sent to the Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) for mycobacterial testing. Empiric treatment with levofloxacin, doxycycline, and
azithromycin was initiated for nontuberculous mycobacterial infection, and the previously prescribed prednisone was
rapidly tapered and stopped. At CDC, immunohistochemical testing of tissue for mycobacteria showed extensive bacilli. DNA extracted from biopsy samples was evaluated by
PCR targeting 16s rRNA and the IS2402 insertion element
(5). Sequences of IS2404 amplicons were 100% identical
with those for Mycobacterium ulcerans. Tissue cultured
(30°C) at CDC grew AFB after 3 months (toe specimen)
and 4 months (calf specimen); 16S rRNA gene sequencing
confirmed a Mycobacterium species, most closely matching M. marinum or M. ulcerans.
Therapy, guided by World Health Organization recommendations (1), was changed to rifampin (900 mg/day
or 10 mg/kg bodyweight), clarithromycin (1,000 mg/day),
and moxifloxacin (400 mg/day). In February 2014, after
15 months’ of antimicrobial drug treatment, debridement,
and skin grafting to the left foot, the lesions were completely healed.
Conclusions
Imported M. ulcerans disease is exceedingly rare, even
in today’s age of global travel. When the infection does
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Figure. Progression of lesions caused by Mycobacterium ulcerans infection before, during, and after treatment. A–C) Left foot before
treatment. D) Left lower leg during treatment. E) Right calf before treatment. F) Right calf after treatment. G, H) Left foot after treatment.

occur, diagnosis is often delayed. In addition to the case
reported here, 3 other cases imported to the United States
have been reported in the literature since 1967 (2–4).
The 4 M. ulcerans cases diagnosed in the United States
were in men (median age 35 years, range 20–63) (Table).
Lesions were located on the upper (25%) and lower (75%)
extremities, similar to cases in Africa, where lesions commonly develop on the extremities of adults and on the
trunk, head, neck, and upper limbs of children (6). Specific
exposures were not identified in 3 of the US patients; the
fourth had exposure to fresh water, a known risk factor (6).
The 2012 imported US case is similar to cases in Australia,
where patients have a median age of 61 years at diagnosis,
and most have single lesions (95%) involving lower limbs
(61%). However, in Australia, the median time from symptom onset to diagnosis is 42 days, consistent with greater
familiarity with the disease (7).
The 3 persons with the prior cases of imported M. ulcerans disease in the United States had traveled to western Africa; the case-patient described herein had returned
from Australia. Most M. ulcerans cases in Australia are
linked to temperate, coastal Victoria and tropical, northern
Queensland (8). Persons with cases imported to other M.

ulcerans–nonendemic countries mostly traveled to Africa
(1 traveled to South America), where the disease is present
but uncommon (9–12).
In regions where M. ulcerans disease is endemic, it is
readily recognized on the basis of lesion appearance and
chronicity. In areas of Australia where Buruli ulcer disease is nonendemic, diagnosis is delayed (13). A hallmark
of imported cases is the difficulty in arriving at a diagnosis
due to nonfamiliarity with the disease. For the 4 imported
US cases, the median time to empiric antimycobacterial
therapy was 20 weeks, and the median time to definitive
diagnosis was 8 months. The differential diagnosis for M.
ulcerans disease is broad, spanning infectious and noninfectious etiologies, including filariasis, phycomycosis,
resolving furuncle, and pyoderma gangrenosum. Samples
from the case-patients were uniformly AFB smear-positive, and for 1 case in which the culture failed to grow M.
ulcerans, diagnosis was made by clinical and epidemiologic history and presence of AFB in tissue. Because the
organism is slow growing, prolonged culture (>3 months)
at low temperatures is required. A hallmark of M. ulcerans histopathology is the absence of granulomas and
presence of extensive necrosis caused by the organism’s
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Table. Characteristics of persons with Mycobacterium ulcerans infection diagnosed and treated in the United States but acquired in a
different country*
Time, wk, to
Final
Time,
Length, mo,
Patient
Location
Risk
Travel
first drug
treatment
mo, to
of drug
Surgical
no., age, y of ulcer
factor
history
therapy
regimen
diagnosis
therapy
management
Outcome
1, 20
Left foot
None
Nigeria
20
Lamprene,
–
–
Amputation
Amputation
clofazimine
below knee
2, 34
Right
None
Nigeria
–
Surgery alone
7
–
Debridement
Cure
elbow
and splitthickness skin
grafting
3, 36
Left calf
Fresh
Northern,
17
Clarithromycin
8
18
Debridement
Cure
Water
western,
and
and splitand
ciprofloxacin
thickness skin
Central
grafting
Africa
4, 63
Right calf Hiking in
QLD,
36
Rifampin,
9
15
Debridement
Cure
and left
Daintree
Australia
clarithromycin,
and splitfoot
Rainforest
moxifloxacin
thickness skin
in sandals
grafting

*All patients were male. Except for negative smear results for patient 1, culture and smear results for all patients were positive. QLD, Queensland; –,
Information not available.

secretion of mycolactone toxin, which suppresses the
host’s immune response (7). The absence of granulomas
on hematoxylin and eosin staining may result in tissue not
being stained for AFB unless clinicians have a high index of suspicion. Furthermore, depending on the bacterial
load and focal distribution, bacteria may not be detected
by AFB staining. Molecular analysis of tissue is the most
sensitive and specific method for rapid and confirmatory
diagnosis of M. ulcerans and should be pursued when disease is suspected (14).
Treatment of M. ulcerans disease has changed markedly over the last several decades. Prior to the early 2000s,
availability of effective drugs was limited, so surgery was
the primary treatment. However, combination therapy with
streptomycin, rifampin, and surgery (including skin grafting) has been shown to be effective (1), and some cases can
be managed with medical therapy alone. Standard antimicrobial treatment, according to World Health Organization
guidelines, consists of administering rifampin (10 mg/kg
body weight daily by mouth) for 8 weeks and streptomycin (15 mg/kg body weight daily by intramuscular injection) for 8 weeks (1). Extensive clinical experience has also
shown a combination of oral antimicrobial drugs (rifampin
with clarithromycin or moxifloxacin) to be effective against
Buruli ulcer disease (15). Of the 4 reported US cases, 1 required surgery alone and 3 required drug treatment and surgery. Response to therapy has been favorable: 2 US cases
were cured by treatment with oral antimicrobial drugs.
Because awareness of Buruli ulcer disease is limited in
regions where M. ulcerans is nonendemic, the potential for
delayed diagnosis in such areas is increased. For persons
with recent travel from M. ulcerans–endemic regions, Buruli ulcer disease should be considered in the differential
diagnoses of unusual chronic cutaneous ulcers and skin ulcers nonresponsive to conventional therapy.
1878
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